Synaptic location is a determinant of the detrimental effects of α-Synuclein pathology to glutamatergic transmission in the basolateral amygdala

Abstract

The presynaptic protein α-synuclein (αSyn) has been suggested to be involved in the pathogenesis of Parkinson’s disease (PD). In PD, the amygdala is prone to develop insoluble αSyn aggregates, and it has been suggested that circuit dysfunction involving the amygdala contributes to the psychiatric symptoms. Yet, how αSyn aggregates affect amygdala function is unknown. In this study, we examined αSyn in glutamatergic axon terminals and the impact of its aggregation on glutamatergic transmission in the basolateral amygdala (BLA). We found that αSyn is primarily present in the vesicular glutamate transporter 1-expressing (vGluT1+) terminals in mouse BLA, which is consistent with higher levels of αSyn expression in vGluT1+ glutamatergic neurons in the cerebral cortex relative to the vGluT2+ glutamatergic neurons in the thalamus. We found that αSyn aggregation selectively decreased the cortico-BLA, but not the thalamo-BLA, transmission; and that cortico-BLA synapses displayed enhanced short-term depression upon repetitive stimulation. In addition, using confocal microscopy, we found that vGluT1+ axon terminals exhibited decreased levels of soluble αSyn, which suggests that lower levels of soluble αSyn might underlie the enhanced short-term depression of cortico-BLA synapses. In agreement with this idea, we found that cortico-BLA synaptic depression was also enhanced in αSyn knockout mice. In conclusion, both basal and dynamic cortico-BLA transmission were disrupted by abnormal aggregation of αSyn and these changes might be relevant to the perturbed cortical control of the amygdala that has been suggested to play a role in psychiatric symptoms in PD.

Data availability

All source data associated with the revised manuscript have been deposited on Open Science Framework: https://doi.org/10.17605/OSF.IO/264SM.All data generated or analyzed during this study are included in the manuscript and source data have been provided for all main and supplementary figures.

Article and author information

Author details

  1. Liqiang Chen

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3236-1129
  2. Chetan Nagaraja

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
  3. Samuel Daniels

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
  4. Zoe A Fisk

    Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada
    Competing interests
    No competing interests declared.
  5. Rachel Dvorak

    Department of Neurodegenerative Science, Van Andel Institute, GRand Rapids, United States
    Competing interests
    No competing interests declared.
  6. Lindsay Meyerdirk

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
  7. Jennifer A Steiner

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0953-1310
  8. Martha L Escobar Galvis

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8400-9392
  9. Michael X Henderson

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    Competing interests
    No competing interests declared.
  10. Maxime WC Rousseaux

    Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada
    Competing interests
    No competing interests declared.
  11. Patrik Brundin

    Pharma Research and Early Development (pRED), F. Hoffmann-La Roche, Little Falls, United States
    Competing interests
    Patrik Brundin, has received support as a consultant from AbbVie, Axial Therapeutics., Calico Life Sciences, CuraSen, Enterin Inc, Fujifilm-Cellular Dynamics International, Idorsia Pharmaceuticals, Lundbeck A/S. He has received commercial support for research from Lundbeck A/S and F. Hoffman-La Roche. He has ownership interests in Acousort AB, Axial Therapeutics, Enterin Inc and RYNE Biotechnology. During the time that this paper was undergoing revision he became an employee of F. Hoffman-La Roche, although none of the data were generated by this company..
  12. Hong-Yuan Chu

    Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
    For correspondence
    hongyuan.chu@vai.org
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0923-683X

Funding

Brain and Behavior Research Foundation

  • Hong-Yuan Chu

Congressionally Directed Medical Research Programs

  • Hong-Yuan Chu

Aligning Science Across Parkinson's (ASAP-020616)

  • Michael X Henderson
  • Maxime WC Rousseaux
  • Hong-Yuan Chu

Aligning Science Across Parkinson's (ASAP-020625)

  • Maxime WC Rousseaux

Aligning Science Across Parkinson's (ASAP-020572)

  • Hong-Yuan Chu

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Jun Ding, Stanford University, United States

Ethics

Animal experimentation: All animal studies were reviewed and approved by the Institutional Animal Care and Use Committee at Van Andel Institute (animal use protocol#: 22-02-007).

Version history

  1. Preprint posted: February 20, 2022 (view preprint)
  2. Received: February 20, 2022
  3. Accepted: June 27, 2022
  4. Accepted Manuscript published: July 1, 2022 (version 1)
  5. Version of Record published: July 15, 2022 (version 2)

Copyright

© 2022, Chen et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,330
    views
  • 637
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Liqiang Chen
  2. Chetan Nagaraja
  3. Samuel Daniels
  4. Zoe A Fisk
  5. Rachel Dvorak
  6. Lindsay Meyerdirk
  7. Jennifer A Steiner
  8. Martha L Escobar Galvis
  9. Michael X Henderson
  10. Maxime WC Rousseaux
  11. Patrik Brundin
  12. Hong-Yuan Chu
(2022)
Synaptic location is a determinant of the detrimental effects of α-Synuclein pathology to glutamatergic transmission in the basolateral amygdala
eLife 11:e78055.
https://doi.org/10.7554/eLife.78055

Share this article

https://doi.org/10.7554/eLife.78055

Further reading

    1. Genetics and Genomics
    2. Neuroscience
    Bohan Zhu, Richard I Ainsworth ... Javier González-Maeso
    Research Article

    Genome-wide association studies have revealed >270 loci associated with schizophrenia risk, yet these genetic factors do not seem to be sufficient to fully explain the molecular determinants behind this psychiatric condition. Epigenetic marks such as post-translational histone modifications remain largely plastic during development and adulthood, allowing a dynamic impact of environmental factors, including antipsychotic medications, on access to genes and regulatory elements. However, few studies so far have profiled cell-specific genome-wide histone modifications in postmortem brain samples from schizophrenia subjects, or the effect of antipsychotic treatment on such epigenetic marks. Here, we conducted ChIP-seq analyses focusing on histone marks indicative of active enhancers (H3K27ac) and active promoters (H3K4me3), alongside RNA-seq, using frontal cortex samples from antipsychotic-free (AF) and antipsychotic-treated (AT) individuals with schizophrenia, as well as individually matched controls (n=58). Schizophrenia subjects exhibited thousands of neuronal and non-neuronal epigenetic differences at regions that included several susceptibility genetic loci, such as NRG1, DISC1, and DRD3. By analyzing the AF and AT cohorts separately, we identified schizophrenia-associated alterations in specific transcription factors, their regulatees, and epigenomic and transcriptomic features that were reversed by antipsychotic treatment; as well as those that represented a consequence of antipsychotic medication rather than a hallmark of schizophrenia in postmortem human brain samples. Notably, we also found that the effect of age on epigenomic landscapes was more pronounced in frontal cortex of AT-schizophrenics, as compared to AF-schizophrenics and controls. Together, these data provide important evidence of epigenetic alterations in the frontal cortex of individuals with schizophrenia, and remark for the first time on the impact of age and antipsychotic treatment on chromatin organization.

    1. Neuroscience
    Aedan Yue Li, Natalia Ladyka-Wojcik ... Morgan Barense
    Research Article

    Combining information from multiple senses is essential to object recognition, core to the ability to learn concepts, make new inferences, and generalize across distinct entities. Yet how the mind combines sensory input into coherent crossmodal representations - the crossmodal binding problem - remains poorly understood. Here, we applied multi-echo fMRI across a four-day paradigm, in which participants learned 3-dimensional crossmodal representations created from well-characterized unimodal visual shape and sound features. Our novel paradigm decoupled the learned crossmodal object representations from their baseline unimodal shapes and sounds, thus allowing us to track the emergence of crossmodal object representations as they were learned by healthy adults. Critically, we found that two anterior temporal lobe structures - temporal pole and perirhinal cortex - differentiated learned from non-learned crossmodal objects, even when controlling for the unimodal features that composed those objects. These results provide evidence for integrated crossmodal object representations in the anterior temporal lobes that were different from the representations for the unimodal features. Furthermore, we found that perirhinal cortex representations were by default biased towards visual shape, but this initial visual bias was attenuated by crossmodal learning. Thus, crossmodal learning transformed perirhinal representations such that they were no longer predominantly grounded in the visual modality, which may be a mechanism by which object concepts gain their abstraction.